DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

Information source: University of Michigan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Implant

Intervention: Teriparatide (Drug); Placebo (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: University of Michigan

Official(s) and/or principal investigator(s):
Jill Bashutski, DDS, MS, Principal Investigator, Affiliation: Faculty


Good bone healing and bone build-up are necessary for the success of dental implants. Research in animals and humans has shown that a drug, called Forteo, can increase bone build-up and bone strength over time. Forteo has been approved by the Food and Drug Administration (FDA) for use in patients with a condition where bone is broken down and weakened, called osteoporosis. The investigators do not know, however, whether Forteo is effective for use in humans for improving bone healing after implant placement, and whether it will have the same bone-building and bone-strengthening effects as for patients with osteoporosis. This research study is being done to learn what effect 7 weeks of treatment with Forteo will have on bone build-up and strengthening of bone for patients receiving implants.

Clinical Details

Official title: The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Bone formation rate

Secondary outcome: bone turnover

Detailed description: A single center, placebo-controlled, double blind parallel study of teriparatide use in patients requiring dental implant therapy is planned. Subjects who qualify based on the inclusion/exclusion criteria will be randomly placed into one of two treatment groups, teriparatide (20 μg/day) or placebo control. Both patients and investigators will be blinded. Serum and gingival crevicular fluid (GCF) samples, radiographs, and a tetracycline-labelled bone core will constitute the main data gathered for analysis. After implant surgery, patients will return at 2 weeks for post-operative care and then at 14 weeks for an implant impression and again at 16 weeks to receive the final restoration. Twelve months after implant placement, patients will be seen for a follow-up exam and standardized radiograph to ensure proper healing.


Minimum age: 30 Years. Maximum age: 85 Years. Gender(s): Both.


Inclusion Criteria:

- Age range 30-85 yrs

- Sex: male and female (female subjects must be postmenopausal, surgically sterilized

or utilizing birth control or abstinence throughout the period of Teriparatide administration)

- Subjects must be able and willing to follow study procedures and instructions;

- Subjects must have read, understood and signed an informed consent form;

- Subjects must have a need for the replacement of at least one tooth in the mandibular

premolar/molar region with at least 12 months since the tooth extraction.

- Sites must be adaptable for dental implant placement without the necessity for

grafting. Exclusion Criteria:

- Subjects under 30 years or over 85 years of age,

- Female subjects who are pregnant, lactating, or female subjects who are of

childbearing potential who are not using contraceptives,

- Subjects with metabolic bone diseases such as Paget's disease, hypercalcemia (mild to

moderate hypocalcemia is acceptable for entry into the study), moderate to severe vitamin D3 abnormalities (If vitamin D levels are below 16 ng/ml and patient exhibits interest, dietary supplementation will be suggested and levels re-evaluated after 4 weeks and reconsidered for inclusion at that time), any other metabolic bone diseases including osteoporosis,

- Subjects with prior radiation therapy, bone metastases or other skeletal malignancy,

- Subjects on medications that would affect bone metabolism,

- Subjects with growth hormone deficiency,

- Subjects with uncontrolled diabetes, sprue, inflammatory bowel disease or other

disorders that would affect calcium absorption

- Subjects that are heavy smokers (> 1 pack/d),

- Subjects with tetracycline sensitivity or allergy,

- Subjects on bisphosphonates,

- Subjects with any form of kidney disease including kidney stones (urolithiasis and


- Subjects with known allergies to tetracycline and/or demeclocycline,

Locations and Contacts

Michigan Center for Oral Health Research, Ann Arbor, Michigan 48106, United States
Additional Information

Related publications:

Hanley, D., et al., Pharmacologic mechanisms of therapeutics:Parathyroid Hormone, in Principles of Bone Biology, J. Bilezikian, L. Raisz, and T. Martin, Editors. 2008, Academic Press: San Diego. p. 1661-1695.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41.

Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005 Apr;87(4):731-41.

Chen H, Frankenburg EP, Goldstein SA, McCauley LK. Combination of local and systemic parathyroid hormone enhances bone regeneration. Clin Orthop Relat Res. 2003 Nov;(416):291-302.

Starting date: February 2011
Last updated: December 9, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017